SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank20
Studio
Year-over-Year Change

Year-over-year net income growth rate

Latest
-137.10%
↓ 160% vs avg
Percentile
P20
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-52.67%
Historical baseline
PeriodValue
Q4 2025-137.10%
Q3 2025549.32%
Q2 2025-94.63%
Q1 202554.39%
Q4 2024-10.10%
Q3 2024-41.09%
Q2 2024-45.96%
Q1 202478.01%
Q4 2023-348.00%
Q3 202325.85%
Q2 20236.43%
Q1 20236.61%
Q4 2022-11.28%
Q3 2022-48.16%
Q2 2022-584.45%
Q1 2022108.53%
Q4 2021-184.44%
Q3 2021-38.06%
Q2 2021-308.65%
Q1 2021-83.31%
Q4 20200.00%